NovaVive Signs a Co-Operation Agreement with Hoken Biotechnology to Register and Market Amplimune™ in Asia
NovaVive and Hoken Biotechnology have committed to work together to introduce Amplimune™ to Asian markets. Hoken will conduct clinical studies to support regulatory submissions and will be our sales and marketing agent.
Equine Sarcoid Tumor Product Now Available to Canadian Veterinarians
An equine-specific version of Immunocidin® for equine sarcoid tumors is now available to Canadian veterinarians. The new product, Immunocidin® Equine, is packaged in 5mL vials and is approved by the Canadian regulator (CFIA).
NovaVive Presents Data Demonstrating Reduction in Antibiotic Use with MCWF in Young Calves
NovaVive today presented a Research Report at the 2017 ACVIM Forum in National Harbor, Maryland. The report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.